Investor Relations FAQs
Rinri Therapeutics is a private biotechnology company developing the world’s first regenerative cell therapies for hearing loss. The company’s pioneering technology seeks to reverse sensorineural hearing loss (SNHL), the leading form of deafness, through the repair and regeneration of the damaged cytoarchitecture of the inner ear. There are currently no pharmacological treatment options for SNHL patients.
Rinri was founded in Sheffield in 2018 by Professor Marcelo Rivolta – a globally recognised Professor of Sensory Stem Cell Biology. He has been based at the University of Sheffield in the UK since 2001 and has written over 40 papers on the subject, many of which have been published in peer-review journals. The Rivolta Laboratory, which he established at the University of Sheffield, is dedicated to studying the biology and behaviour of auditory stem cells, and to exploring their potential to regenerate the damaged inner ear.
Rinri means ear in Quechua – a native language of South America. Rinri’s founder Professor Marcelo Rivolta is originally from Argentina. You can read more about his background and the establishment of Rinri here.
Its registered offices are based at the Innovation Centre in Sheffield
Rinri Therapeutics is a private company backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, Pioneer Group, the University of Sheffield and the UK Future Fund.
Rinri currently employs 9 full time staff, but with extensive partnering and outsourcing has >40 people dedicated to different projects around the UK and Europe.
You can view the Executive Team and Advisory Board by visiting the Our Company section of the website here.
Our Executive Team and Advisory Board attend conferences and events throughout the year. We would love to meet you there. Please do get in touch to find out where we are heading next.
You can submit questions to Rinri Therapeutics’ investor relations team by contacting email@example.com
Who should I contact if I have any further questions? Please submit questions by contacting firstname.lastname@example.org